These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma]. Bruchovsky N; Goldenberg SL; Rennie PS; Gleave M Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155 [TBL] [Abstract][Full Text] [Related]
6. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma]. DeAntoni E; Crawford ED Urologe A; 1995 Sep; 34(5):382-8. PubMed ID: 7483154 [TBL] [Abstract][Full Text] [Related]
7. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Hedlund PO; Henriksson P Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602 [TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E; J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057 [TBL] [Abstract][Full Text] [Related]
9. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Hedlund PO; Johansson R; Damber JE; Hagerman I; Henriksson P; Iversen P; Klarskov P; Mogensen P; Rasmussen F; Varenhorst E; Scand J Urol Nephrol; 2011 Nov; 45(5):346-53. PubMed ID: 21627403 [TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. Garzotto M; Wajsman Z J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190 [TBL] [Abstract][Full Text] [Related]
11. [Endocrine treatment of prostatic cancer. A renaissance for parenteral estrogen]. Stege R; Sander S Tidsskr Nor Laegeforen; 1993 Mar; 113(7):833-5. PubMed ID: 8480286 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Stege R; Grande M; Carlström K; Tribukait B; Pousette A Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445 [TBL] [Abstract][Full Text] [Related]
15. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium. Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677 [TBL] [Abstract][Full Text] [Related]
16. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
17. Hormonal management of stage D carcinoma of the prostate. Trachtenberg J Urol Clin North Am; 1987 Nov; 14(4):685-94. PubMed ID: 2445092 [TBL] [Abstract][Full Text] [Related]
18. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749 [TBL] [Abstract][Full Text] [Related]